| Literature DB >> 25268698 |
Guohua Yi1, Jang Gi Choi1, Preeti Bharaj1, Sojan Abraham1, Ying Dang1, Tal Kafri2, Ogechika Alozie3, Manjunath N Manjunath1, Premlata Shankar1.
Abstract
CCR5 disruption by zinc finger nucleases (ZFNs) is a promising method for HIV-1 gene therapy. However, successful clinical translation of this strategy necessitates the development of a safe and effective method for delivery into relevant cells. We used non-integrating lentivirus (NILV) for transient expression of ZFNs and pseudotyped the virus with HIV-envelope for targeted delivery to CD4(+) T cells. Both activated and resting primary CD4(+) T cells transduced with CCR5-ZFNs NILV showed resistance to HIV-1 infection in vitro. Furthermore, NILV transduced resting CD4(+) T cells from HIV-1 seronegative individuals were resistant to HIV-1 challenge when reconstituted into NOD-scid IL2rγc null (NSG) mice. Likewise, endogenous virus replication was suppressed in NSG mice reconstituted with CCR5-ZFN-transduced resting CD4(+) T cells from treatment naïve as well as ART-treated HIV-1 seropositive patients. Taken together, NILV pseudotyped with HIV envelope provides a simple and clinically viable strategy for HIV-1 gene therapy.Entities:
Year: 2014 PMID: 25268698 PMCID: PMC4222653 DOI: 10.1038/mtna.2014.52
Source DB: PubMed Journal: Mol Ther Nucleic Acids ISSN: 2162-2531 Impact factor: 10.183